Application of Aspirin for Rheumatoid Arthritis and Myocardial Infarction Treatment
DOI:
https://doi.org/10.54097/ayjt2e24Keywords:
Rheumatoid arthritis, Myocardial Infarction, Treatment.Abstract
With the intensification of the aging process of the population, the disease problems of the elderly are particularly prominent. Rheumatoid arthritis and myocardial infarction are common diseases in the elderly. The main component of aspirin has been used to treat fever since 1763, and then the role of aspirin was discovered by humans. In modern daily life, aspirin is used for anti-inflammation, pain relief, and inhibition of thrombus formation. The subject of this research is how recent experiments demonstrate the effectiveness of aspirin for these two diseases. Research done by different teams has shown that aspirin inhibits a catalyst called COX that catalyzes the production of prostaglandins for rheumatoid arthritis treatment, leading to the relief of skeletal muscle pain and inflammation. In the treatment of myocardial infarction, aspirin prevents the accumulation of platelets to reduce the formation of thrombosis. Among the drug that can treat these two diseases, aspirin can be said to be the most effective drug with the least side effects.
Downloads
References
Arif H, Aggarwal S. Salicylic acid (aspirin). 2018.
Patel D K, Hesse A, Ogunbona A, et al. Metabolism of aspirin after therapeutic and toxic doses. Human & experimental toxicology, 1990, 9 (3): 131-136.
Jeffreys D. Aspirin: the remarkable story of a wonder drug. Bloomsbury Publishing USA, 2008.
Raber I, McCarthy C P, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. The Lancet, 2019, 393 (10186): 2155-2167.
Vane J R. The use of isolated organs for detecting active substances in the circulating blood. British Journal of Pharmacology and Chemotherapy, 1964, 23 (2): 360-373.
Ratchford S M, Lavin K M, Perkins R K, et al. Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle. Journal of Applied Physiology, 2017, 123 (6): 1610-1616.
Gaziano J M, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet, 2018, 392 (10152): 1036-1046.
Patel D K, Hesse A, Ogunbona A, et al. Metabolism of aspirin after therapeutic and toxic doses. Human & experimental toxicology, 1990, 9 (3): 131-136.
Montgomery P R, Berger L G, Mitenko P A, et al. Salicylate metabolism: effects of age and sex in adults. Clinical Pharmacology & Therapeutics, 1986, 39 (5): 571-576.
Buchanan M R, Hirsh J. Effect of aspirin on hemostasis and thrombosis [C] // Allergy and Asthma Proceedings. OceanSide Publications, 1986, 7 (1): 26.
Cryer B, Mahaffey K W. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. Journal of multidisciplinary healthcare, 2014: 137-146.
Gao R, Li X. Risk assessment and aspirin use in Asian and Western populations. Vascular health and risk management, 2010: 943-956.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
